Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2022 07:30 ET | Source: Incyclix Bio

Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital

Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid Subramony, Ph.D., of Boxer Capital to join Incyclix Bio’s board of directors RESEARCH...